NASDAQ:NAMS NewAmsterdam Pharma (NAMS) Stock Forecast, Price & News $9.82 -0.07 (-0.71%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$9.68▼$9.9950-Day Range$9.85▼$12.0252-Week Range$7.52▼$32.88Volume19,660 shsAverage Volume71,919 shsMarket Capitalization$800.92 millionP/E RatioN/ADividend YieldN/APrice Target$21.67 ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media NewAmsterdam Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside120.6% Upside$21.67 Price TargetShort InterestHealthy0.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-1.18Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.92) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector449th out of 961 stocksPharmaceutical Preparations Industry200th out of 448 stocks 3.5 Analyst's Opinion Consensus RatingNewAmsterdam Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.67, NewAmsterdam Pharma has a forecasted upside of 120.6% from its current price of $9.82.Amount of Analyst CoverageNewAmsterdam Pharma has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.91% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NewAmsterdam Pharma has recently decreased by 0.46%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNewAmsterdam Pharma does not currently pay a dividend.Dividend GrowthNewAmsterdam Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NAMS. Previous Next 0.5 News and Social Media Coverage News SentimentNewAmsterdam Pharma has a news sentiment score of -1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NewAmsterdam Pharma this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NewAmsterdam Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.50% of the stock of NewAmsterdam Pharma is held by insiders.Percentage Held by Institutions96.46% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NewAmsterdam Pharma are expected to grow in the coming year, from ($1.92) to ($1.41) per share.Price to Book Value per Share RatioNewAmsterdam Pharma has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NewAmsterdam Pharma (NASDAQ:NAMS) StockNewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Read More NAMS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NAMS Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comNewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 MutationSeptember 20, 2023 | finance.yahoo.comNewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 21, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!August 19, 2023 | msn.comNewAmsterdam Pharma: Best Cardiovascular Biotech In 2023August 16, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: NewAmsterdam Pharma Company (NAMS), Legend Biotech (LEGN)August 10, 2023 | finance.yahoo.comNewAmsterdam Pharma First Half 2023 Earnings: €0.92 loss per share (vs €1.50 profit in 1H 2022)August 7, 2023 | finance.yahoo.comNewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial HighlightsAugust 2, 2023 | finance.yahoo.comRA Capital Management, L.P. Boosts Position in NewAmsterdam Pharma Co NVSeptember 21, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!August 2, 2023 | gurufocus.comRA Capital Management, L.P. Acquires Stake in NewAmsterdam Pharma Co NVJuly 25, 2023 | finance.yahoo.comNewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular DiseaseJuly 17, 2023 | finance.yahoo.comInvesting in NewAmsterdam Pharma (NASDAQ:NAMS) a year ago would have delivered you a 21% gainJuly 4, 2023 | seekingalpha.comNewAmsterdam Pharma: Exciting Cardiovascular Drug Targeting The MarketJune 19, 2023 | seekingalpha.comNewAmsterdam Pharma: Excellent LDL-C Data But Unknown In The U.S.June 9, 2023 | finance.yahoo.comNewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary SharesJune 8, 2023 | finance.yahoo.comAfter Plunging -16.36% in 4 Weeks, Here's Why the Trend Might Reverse for NewAmsterdam Pharma Company N.V. (NAMS)June 7, 2023 | msn.comWhy Shares of NewAmsterdam Pharma Were Plummeting on WednesdayJune 7, 2023 | marketwatch.comNewAmsterdam Pharma Shares Slide After Secondary Offering >NAMSJune 7, 2023 | msn.comNewAmsterdam Pharma shares dip on pricing upsized secondary stock offering at $11.50/shareJune 7, 2023 | finance.yahoo.comNewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary SharesJune 6, 2023 | finance.yahoo.comNewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary SharesJune 6, 2023 | finance.yahoo.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) most popular amongst private equity firms who own 58% of the shares, institutions hold 20%June 5, 2023 | finance.yahoo.comNewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese PatientsJune 3, 2023 | finance.yahoo.comNewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023May 31, 2023 | finance.yahoo.comNewAmsterdam Pharma to Present at Jefferies Healthcare ConferenceMay 23, 2023 | finance.yahoo.comNewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023May 8, 2023 | finanznachrichten.deNewAmsterdam Pharma Company B.V.: NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial HighlightsSee More Headlines Receive NAMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address NAMS Company Calendar Today9/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NAMS CUSIPN/A CIK1936258 Webwww.newamsterdampharma.com Phone352062971FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.67 High Stock Price Forecast$24.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+120.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,230,000.00 Net MarginsN/A Pretax Margin-80.05% Return on Equity-67.45% Return on Assets-33.66% Debt Debt-to-Equity RatioN/A Current Ratio10.15 Quick Ratio12.64 Sales & Book Value Annual Sales$102.74 million Price / Sales7.82 Cash FlowN/A Price / Cash FlowN/A Book Value$6.26 per share Price / Book1.57Miscellaneous Outstanding Shares81,560,000Free Float79,521,000Market Cap$803.37 million OptionableNot Optionable Beta-0.35 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Michael Harvey Davidson FACC (Age 66)Facc., Facp., M.D., CEO, Pres, Exec. Board Member & Director Dr. Johannes Jacob Pieter Kastelein FESC (Age 69)M.D., Ph.D., Founder, Chief Scientific Officer, Member of Exec. Board & Director Ms. Louise Kooij (Age 47)Interim Chief Financial Officer Mr. Douglas F. Kling (Age 50)Chief Operating Officer Mr. Jim JacobsonChief Legal Officer & Sec.Dr. Marc Ditmarsch M.D. (Age 56)Chief Devel. Officer Ms. Lina Gugucheva (Age 36)Chief Bus. Officer Dr. Sheng Cui Ph.D.VP & Head of Chemistry Manufacturing and Controls (CMC)Ms. Annie NeildVP & Head of Regulatory AffairsMr. William Jones Jr. (Age 59)M.B.A., Chief Commercial Officer More ExecutivesKey CompetitorsInnovivaNASDAQ:INVAVerve TherapeuticsNASDAQ:VERVPureTech HealthNASDAQ:PRTCCollegium PharmaceuticalNASDAQ:COLLCassava SciencesNASDAQ:SAVAView All CompetitorsInstitutional OwnershipAffinity Asset Advisors LLCBought 100,000 shares on 8/21/2023Ownership: 0.123%Bain Capital Life Sciences Investors LLCBought 2,173,913 shares on 8/15/2023Ownership: 12.842%RA Capital Management L.P.Bought 5,000,000 shares on 8/15/2023Ownership: 11.035%Schonfeld Strategic Advisors LLCBought 27,200 shares on 8/14/2023Ownership: 0.070%Marshall Wace LLPBought 25,361 shares on 8/14/2023Ownership: 0.031%View All Institutional Transactions NAMS Stock - Frequently Asked Questions Should I buy or sell NewAmsterdam Pharma stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewAmsterdam Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NAMS shares. View NAMS analyst ratings or view top-rated stocks. What is NewAmsterdam Pharma's stock price forecast for 2023? 4 analysts have issued 12-month target prices for NewAmsterdam Pharma's stock. Their NAMS share price forecasts range from $19.00 to $24.00. On average, they anticipate the company's share price to reach $21.67 in the next twelve months. This suggests a possible upside of 120.0% from the stock's current price. View analysts price targets for NAMS or view top-rated stocks among Wall Street analysts. How have NAMS shares performed in 2023? NewAmsterdam Pharma's stock was trading at $10.90 on January 1st, 2023. Since then, NAMS stock has decreased by 9.6% and is now trading at $9.85. View the best growth stocks for 2023 here. What is NewAmsterdam Pharma's stock symbol? NewAmsterdam Pharma trades on the NASDAQ under the ticker symbol "NAMS." Who are NewAmsterdam Pharma's major shareholders? NewAmsterdam Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (12.84%), RA Capital Management L.P. (11.03%), Medicxi Ventures Management Jersey Ltd (3.52%), Affinity Asset Advisors LLC (0.12%), Monashee Investment Management LLC (0.12%) and Schonfeld Strategic Advisors LLC (0.07%). How do I buy shares of NewAmsterdam Pharma? Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NewAmsterdam Pharma's stock price today? One share of NAMS stock can currently be purchased for approximately $9.85. How much money does NewAmsterdam Pharma make? NewAmsterdam Pharma (NASDAQ:NAMS) has a market capitalization of $803.37 million and generates $102.74 million in revenue each year. How can I contact NewAmsterdam Pharma? NewAmsterdam Pharma's mailing address is TWO UNION SQUARE 601 UNION STREET SUITE 3200, SEATTLE WA, 98101. The official website for the company is www.newamsterdampharma.com. The company can be reached via phone at 352062971 or via email at max.nowicki@frazierhealthcare.com. This page (NASDAQ:NAMS) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.